Key Highlights
- The Phase 3 COVE-3 study of YCANTH in common warts has exceeded 50% of its enrollment target.
- Topline data from the study is expected in mid-2027.
- YCANTH (cantharidin, VP-102) is being evaluated as a topical treatment for common warts.
- The enrollment update was disclosed on August 27, 2026.
Enrollment Progress in the COVE-3 Study
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) said on August 27, 2026 that its Phase 3 COVE-3 study, evaluating YCANTH (cantharidin, VP-102) in common warts, has already exceeded 50% of its current target enrollment. Common warts are a widespread dermatologic condition without a single dominant approved pharmacologic treatment, and enrollment pace is often watched as an early indicator of a trial's path to completion.
YCANTH is a proprietary formulation of cantharidin, a compound with a long history of use in wart and molluscum treatment, delivered through Verrica's applicator technology (VP-102).
What Comes Next
With more than half of target enrollment complete, Verrica (NASDAQ:VRCA) has guided to topline data from COVE-3 in mid-2027. That timeline leaves a multi-quarter gap between this enrollment update and the trial's actual efficacy and safety readout, meaning today's disclosure is a process milestone rather than a clinical result.
Common warts, while rarely serious, are persistent and can be difficult to clear with over-the-counter options, leaving room for a prescription therapy with clinical trial support behind its efficacy claims.
Market Reaction
Shares of Verrica Pharmaceuticals (NASDAQ:VRCA) rose 3.26% to $5.07, with the company holding a market Capitalization of roughly $87.1 million. The positive move on an enrollment update, rather than efficacy data, suggests the market is treating faster-than-expected enrollment as a favorable signal for the program's overall timeline.
What is YCANTH being studied for?
YCANTH (cantharidin, VP-102), developed by Verrica Pharmaceuticals (NASDAQ:VRCA), is being studied as a treatment for common warts in the Phase 3 COVE-3 trial.
How much of the trial's enrollment is complete?
As of August 27, 2026, the COVE-3 study had exceeded 50% of its current target enrollment.
When is topline data expected?
Verrica Pharmaceuticals (NASDAQ:VRCA) expects topline data from COVE-3 in mid-2027.



_11_17_2026_20_37_58_946960.jpg)


Please wait processing your request...